MINI FUTURE LONG - UCB Stock

DE000ME2KB21

Real-time Bid/Ask 06:41:55 2024-06-03 am EDT
7.1 ^EUR / 7.11 ^EUR	-1.18%

3 months	+44.96%
6 months	+499.17%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : Acquisition of own shares	May. 31	PU
UCB : Commitment to Innovation in Drug Development	May. 29	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	May. 23	PU
UCB - Acquisition of own shares	May. 20	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-03	7.05	-1.95%
24-05-31	7.19	+2.86%
24-05-30	6.99	-0.85%
24-05-29	7.05	-0.70%
24-05-28	7.1	-0.84%

Delayed Quote Börse Stuttgart

Last update June 03, 2024 at 03:42 am EDT

More quotes

Static data

Product type	Knock-Out con Stop Loss
Buy / Sell	CALL
Underlying	UCB
Issuer	Morgan Stanley
WKN	ME2KB2
ISIN	DE000ME2KB21
Date issued	2023-10-25
Strike	56.82 €
Maturity	Unlimited
Parity	10 : 1
Emission price	1.59 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	7.25 €
Lowest since issue	1.05 €
Spread	0.01 €
Spread %	0.14%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

128.6 EUR

Average target price

126.4 EUR

Spread / Average Target

-1.76%

Consensus